Abstract
In this study, we compared the success rate of eradicating Helicobacter pylori (H. pylori) in adults and children using vonoprazan (VPZ)-based H. pylori regimens to that of proton pump inhibitors (PPIs). In Japan, the success rate of a VPZ-based regimen as first-line therapy was lower in children than in adults. Compared with adults, children around puberty have higher CYP2C19 and CYP3A4 enzymatic activity to metabolize PPIs and VPZ. Further, children generally have shorter intestinal transit times than adults and may absorb antibiotics to a lesser extent. When comparing success rates of pediatric and adult eradication therapy using VPZ, it is very important to maintain a higher intragastric pH with sufficient gastric acid suppression to maintain H. pylori in a replicating state and amoxicillin and clarithromycin in the intestinal tract for as long as possible by reducing diarrhea as a side effect. Based on the above, it is reasonable that VPZ, which can suppress stomach acids more strongly than PPI, is a more relevant H. pylori eradication therapy.
1 Introduction
Previous research suggested that vonoprazan (VPZ)-based Helicobacter pylori (H. pylori) regimens for eradication therapy had a superior eradication efficacy than frequently used proton pump inhibitor (PPI)-based regimens in adults (Murakami et al., 2016; Lyu et al., 2019; Sun et al., 2022). VPZ is a new, potent acid-inhibitory drug, which competitively inhibits potassium binding to the hydrogen-potassium ATPase in gastric parietal cells more efficiently than PPIs (Abdel-Aziz et al., 2021). Therefore, VPZ-based regimens facilitate a shorter eradication therapy and potentially provide significantly higher eradication rates of clarithromycin-resistant strains. To examine why VPZ-based H. pylori regimens for eradication therapy were more effective in eradicating H. pylori than PPI regimens, we compared its success rate for H. pylori eradication in adults and children.
2 Helicobacter pylori eradication success rate between adults and children
Table 1 shows that the first-line H. pylori eradication therapy’s success rate by VPZ, amoxicillin (AMPC) and clarithromycin (CAM) for 7 days in Japan, and divided it into adults and children. All these data were previously reported. Considering regional H. pylori genotype, I intentionally limited the reports from Japan and omitted the results using second-line H. pylori eradication therapy, VPZ dual therapy, and metronidazole. VPZ-based regimen as first-line therapy’s success rate in children was lower than those in adults.
TABLE 1
| Authors year | Study design | Number | Regimen | Drug doses VPZ, AMPC, CAM twice for day | Duration (days) | CAM Resistance rate | Success rate | |
|---|---|---|---|---|---|---|---|---|
| Adult | Murakami et al. (2016) | RCT | 329 | VPZ + AMPC + CAM | 20, 750, 200 or 400 mg | 7 | 38.3% | 92.6% (ITT) |
| Suzuki et al. (2016) | ROS | 181 | VPZ + AMPC + CAM | 20, 750, 200 mg | 7 | N/A | 91.2% (PP), 89.1% (ITT) | |
| Tsujimae et al. (2016) | POS | 439 | VPZ + AMPC + CAM | 20, 750, 200 mg | 7 | N/A | 86.3% (PP), 84.6% (ITT) | |
| Tanabe et al. (2017) | ROS | 363 | VPZ + AMPC + CAM | 20, 750, 200 or 400 mg | 7 | 23.5% | 94.4% (PP), 87.2% (ITT) | |
| Takara et al. (2019) | POS | 189 | VPZ + AMPC + CAM | 20, 750, 200 mg | 7 | N/A | 91.0% (ITT) | |
| Ozaki et al. (2018) | POS | 1,688 | VPZ + AMPC + CAM | 20, 750, 200 or 400 mg | 7 | N/A | 90.8% (ITT) | |
| Suzuki et al. (2020) | RCT | 167 | VPZ + AMPC + CAM | 20, 750, 200 mg | 7 | 25.6% | 90.2% (PP), 89.2% (ITT) | |
| Child | Kusano et al. (2017) | POS | 118 | VPZ + AMPC + CAM | 20, 750, 200 mg | 7 | N/A | 85.7% (PP), 81.3% (ITT) |
| Kakiuchi et al. (2019) | POS | 501 | VPZ + AMPC + CAM | 20, 750, 200 mg | 7 | N/A | 85.1% (PP) | |
| Kaji et al. (2020) | POS | 144 | VPZ + AMPC + CAM | 20, 750, 200 mg | 7 | N/A | 83.8% (PP), 82.6% (ITT) | |
| Gotoda et al. (2020) | POS | 161 | VPZ + AMPC + CAM | 20, 750, 200 mg | 7 | N/A | 84.0% (PP), 81.9% (ITT) | |
| Kakiuchi et al. (2022) | POS | 83 | VPZ + AMPC + CAM | 20, 750, 200 mg | 7 | 57.8% | 81.9% (ITT) | |
| Kakiuchi et al. (2023) | POS | 836 | VPZ + AMPC + CAM | 20, 750, 200 mg | 7 | N/A | 84.0% (PP), 73.6% (ITT) |
List of manuscripts on Helicobacter pylori eradication therapy success rate using vonoprazan as first-line agent in Japan.
RCT, randomized controlled trial; ROS, retrospective observational study; POS, prospective observational study; VPZ, vonoprazan; AMPC, amoxicillin; N/A, not applicable; CAM, clarithromycin; ITT, intention-to-treat; PP, per protocol.
3 Discussion
There were three possible reasons why the eradication rate of adults using VPZ was higher than that of children. First, adolescents tend to have a higher rate of H. pylori CAM resistance. It has been reported that the H. pylori CAM resistance rate is high among young people in Japan (Okamura et al., 2014), which is believed to be a result of the frequent CAM prescription use for childhood respiratory tract infections in this generation (Tsuboi and Iinuma, 2021). Among CAM-resistant strains, VPZ has a significantly higher eradication success rate than PPI (Murakami et al., 2016; Okubo et al., 2020), suggesting that it is important to suppress acid and make AMPC, not CAM, more effective. In addition, sufficient acid suppression is crucial for effectiveness because, bacteria enter their replicative state and become susceptible to AMPC and CAM at high pH. Second, children around puberty have higher CYP2C19 and CYP3A4 enzyme activity to metabolize PPIs and VAP (Anderson and Lynn, 2009). As a result, children metabolize VAP more rapidly than adults and may be attenuated at a higher rate than adults. Third, it has been reported that the ionized agent absorption (many antibacterial agents) that are poorly lipophilic is affected by the small bowel transit time (Martinez and Amidon, 2002). Children generally have shorter intestinal transit times than adults and may absorb less antibiotics than adults. This may be supported by our report (Kakiuchi et al., 2021) that diarrhea during eradication therapy reduces H. pylori eradication success rate. The former two suggests that sufficient gastric acid suppression is important for H. pylori eradication. The last reason suggests the importance of sufficient antibiotic absorption for H. pylori eradication. Graham (Graham DY, 2023) demonstrated that H. pylori eradication was successfully achieved by high intragastric concentrations of antibiotics or an intragastric pH at which amoxicillin is active.
In contrast, the efficacy of a VPZ-based regimen in a Western adult population was not higher compared with that in an Asian population (Chey WD et al., 2022). VPZ is mainly metabolized by CYP3A4 enzyme. Given the lack of clinically significant differences in VPZ pharmacokinetics between Asian and non-Asian populations, the differences between studies conducted among Western adults and Japanese populations are most likely not due to race alone. Different treatment compliance rates may also have contributed to outcome differences. With respect to children, there is no data regarding the eradication of H. pylori using VPZ in Western countries; therefore, we could not compare its eradication success rate between populations of Asian, including Japan, and Western countries.
In conclusion, a comparison of pediatric and adult eradication therapy success rates using VPZ could reinforce the following conclusions: with regard to H. pylori eradication therapy, it is very important to maintain a higher intragastric pH with sufficient gastric acid suppression to keep H. pylori in a replicating state and to keep AMPC and CAM in the intestinal tract as long as possible by reducing diarrhea as a side effect. It is reasonable that VPZ, which is more potent in stomach acid suppression than PPI, should gain a dominant position in H. pylori eradication therapy.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Ethics statement
Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.
Author contributions
TK searched the literature. TK conceived and wrote the manuscript. TK contributed to the manuscript and approved the submitted version.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Abdel-AzizY.MetzD. C.HowdenC. W. (2021). Review article: Potassium-competitive acid blockers for the treatment of acid-related disorders. Alimentary Pharmacol. Ther.53 (7), 794–809. 10.1111/apt.16295
2
AndersonG. D.LynnA. M. (2009). Optimizing pediatric dosing: A developmental pharmacologic approach. Pharmacotherapy29 (6), 680–690. 10.1592/phco.29.6.680
3
CheyW. D.MégraudF.LaineL.LópezL. J.HuntB. J.HowdenC. W. (2022). Vonoprazan triple and dual therapy for helicobacter pylori infection in the United States and europe: Randomized clinical trial. Gastroenterology163 (3), 608–619. 10.1053/j.gastro.2022.05.055
4
GotodaT.KusanoC.SuzukiS.HoriiT.IchijimaR.IkeharaH. (2020). Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan. J. gastroenterology55 (10), 969–976. 10.1007/s00535-020-01709-4
5
GrahamD. Y. (2023). Why the vonoprazan helicobacter pylori therapies in the US-European trial produced unacceptable cure rates. Dig. Dis. Sci.68 (5), 1691–1697. 10.1007/s10620-023-07886-5
6
KajiE.YodenA.OtaniM.OkuhiraT.AomatsuT.TamaiH.et al (2020). Helicobacter pylori test-and-treat strategy for second-year junior high school students aimed at the prevention of gastric cancer in Takatsuki City. Helicobacter25, e12696. 10.1111/hel.12696
7
KakiuchiT.MatsuoM.EndoH.NakayamaA.SatoK.TakamoriA.et al (2019). A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in saga prefecture: A preliminary report. J. gastroenterology54 (8), 699–707. 10.1007/s00535-019-01559-9
8
KakiuchiT.MatsuoM.EndoH.SakataY.EsakiM.NodaT.et al (2023). Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: A prospective multicenter study. J. gastroenterology58 (3), 196–204. 10.1007/s00535-022-01942-z
9
KakiuchiT.MatsuoM.EndoH.SakataY.EsakiM.NodaT.et al (2021). Gastrointestinal adverse reactions reduce the success rate of Helicobacter pylori eradication therapy: A multicenter prospective cohort study. Helicobacter26 (2), e12776. 10.1111/hel.12776
10
KakiuchiT.OkudaM.MatsuoM.FujimotoK. (2022). Smart Gene™ as an effective non-invasive point-of-care test to detect Helicobacter pylori clarithromycin-resistant mutation. J. Gastroenterol. Hepatol.37 (9), 1719–1725. 10.1111/jgh.15887
11
KusanoC.GotodaT.IshikawaH.MoriyamaM. (2017). The administrative project of Helicobacter pylori infection screening among junior high school students in an area of Japan with a high incidence of gastric cancer. Gastric Cancer20 (Suppl. 1), 16–19. 10.1007/s10120-017-0688-7
12
LyuQ. J.PuQ. H.ZhongX. F.ZhangJ. (2019). Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. Biomed. Res. Int.2019, 9781212. 10.1155/2019/9781212
13
MartinezM. N.AmidonG. L. (2002). A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. J. Clin. Pharmacol.42 (6), 620–643. 10.1177/00970002042006005
14
MurakamiK.SakuraiY.ShiinoM.FunaoN.NishimuraA.AsakaM. (2016). Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind study. Gut65 (9), 1439–1446. 10.1136/gutjnl-2015-311304
15
OkamuraT.SugaT.NagayaT.ArakuraN.MatsumotoT.NakayamaY.et al (2014). Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: A multi-generational comparison. Helicobacter19 (3), 214–220. 10.1111/hel.12124
16
OkuboH.AkiyamaJ.KobayakawaM.KawazoeM.MishimaS.TakasakiY.et al (2020). Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility. J. gastroenterology55 (11), 1054–1061. 10.1007/s00535-020-01723-6
17
OzakiH.HaradaS.TakeuchiT.KawaguchiS.TakahashiY.KojimaY.et al (2018). Vonoprazan, a novel potassium-competitive acid blocker, should be used for the helicobacter pylori eradication therapy as first choice: A large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for helicobacter pylori eradication therapy. Digestion97 (3), 212–218. 10.1159/000485097
18
SunY.YueL.HuW. (2022). Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: A meta-analysis of randomized clinical trials. Eur. J. Clin. Pharmacol.79 (2), 279–288. 10.1007/s00228-022-03430-y
19
SuzukiS.GotodaT.KusanoC.IkeharaH.IchijimaR.OhyauchiM.et al (2020). Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: A multicentre randomised trial in Japan. Gut69 (6), 1019–1026. 10.1136/gutjnl-2019-319954
20
SuzukiS.GotodaT.KusanoC.IwatsukaK.MoriyamaM. (2016). The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am. J. gastroenterology111 (7), 949–956. 10.1038/ajg.2016.182
21
TakaraY.EndoH.NakanoR.KawachiK.HidakaH.MatsunagaT.et al (2019). Smoking and drinking did not increase the failure of therapeutic helicobacter pylori eradication by vonoprazan, clarithromycin, and amoxicillin. Digestion99 (2), 172–178. 10.1159/000490889
22
TanabeH.AndoK.SatoK.ItoT.GotoM.SatoT.et al (2017). Efficacy of vonoprazan-based triple therapy for helicobacter pylori eradication: A multicenter study and a review of the literature. Dig. Dis. Sci.62 (11), 3069–3076. 10.1007/s10620-017-4664-1
23
TsuboiI.IinumaK. (2021). Immunochromatography-application example and POCT type genetic testing. Chem. Pharm. Bull.69 (10), 984–988. 10.1248/cpb.c21-00164
24
TsujimaeM.YamashitaH.HashimuraH.KanoC.ShimoyamaK.KanamoriA.et al (2016). A comparative study of a new class of gastric acid suppressant agent named vonoparazan versus esomeprazole for the eradication of helicobacter pylori. Digestion94 (4), 240–246. 10.1159/000454762
Summary
Keywords
Helicobacter pylori, vonoprazan, proton pump inhibitor, child, adult
Citation
Kakiuchi T (2023) Effectiveness of vonoprazan-based regimens compared with proton pump inhibitor-based regimens as first-line Helicobacter pylori agents. Front. Pharmacol. 14:1216433. doi: 10.3389/fphar.2023.1216433
Received
03 May 2023
Accepted
12 July 2023
Published
19 July 2023
Volume
14 - 2023
Edited by
Karunakaran Kalesh, Teesside University, United Kingdom
Reviewed by
Mitsushige Sugimoto, Tokyo Medical University Hospital, Japan
Updates
Copyright
© 2023 Kakiuchi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Toshihiko Kakiuchi, kakiucht@cc.saga-u.ac.jp
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.